← Back to Browse

Ocular Therapeutix, Inc.

OCUL • Healthcare

1
Grade F
Compass
Current Price
$9.24
Market Cap
$2.7B

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Quality Assessment

Ocular Therapeutix, Inc. is a high-risk healthcare company with a Compass Score of 1. This stock has poor quality metrics and high risk. Not recommended for conservative investors.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Technical Overview

Click any metric for details

Wall Street View

Consensus
N/A
Analysts
6
Price Target
๐Ÿ”’
Upside
๐Ÿ”’

Growth Projections

Projected EPS Growth
๐Ÿ”’
Projected Revenue Growth
๐Ÿ”’

Financial Health

Click any metric for details

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.